1
|
POS1228 IMPACT OF COVID-19 ON THE PRESCRIPTION OF BIOLOGIC DMARDs: A POPULATION-LEVEL STUDY IN ENGLAND. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThere has been considerable uncertainty about the impact of biologic DMARDs (bDMARDs) on COVID-19 morbidity and vaccine efficacy, which may have influenced prescribing during the pandemic.ObjectivesTo assess trends in the prescription of three commonly used bDMARDs with different modes of action - adalimumab (ADA), rituximab (RTX) and tocilizumab (TOC) - in England before and during the COVID-19 pandemic.MethodsThe National Health Service (NHS) Secondary Care Medicines dataset was utilised to analyse temporal trends in bDMARD prescriptions issued by all NHS hospital pharmacies in England. Monthly averages of prescriptions issued for ADA, RTX and TOC for combined indications, standardised using WHO Defined Daily Doses (DDD), were described from January 2019 to November 2021. Interrupted time-series analyses (ITSA) were used to estimate the effect of the pandemic on prescription trends for ADA, RTX and TOC; Newey-West standard errors with lags were used to account for autocorrelation between observation periods in these models.ResultsTemporal trends in ADA, RTX and TOC prescriptions are shown in Figure 1. A 46% decrease in RTX prescriptions was observed between March and April 2020, from 1,338,300 DDD to 718,900 DDD, respectively, coinciding with the worsening COVID-19 pandemic in England. RTX prescriptions increased after May 2020, reflected in the positive prescription trend observed in ITSA models (Table 1); however, RTX prescriptions remained below pre-pandemic levels, before decreasing again between November 2020 and February 2021. This coincided with increasing COVID-19 case numbers in England.Table 1.Trends in prescriptions issued for ADA, RTX and TOC in England before and after the onset of the COVID-19 pandemic, assessed using interrupted time-series analyses. The absolute change in prescriptions issued in March 2020, relative to April 2020, is shown.RituximabAdalimumabTocilizumabPrescription trend before March 2020-0.23% per year(95% CI -0.97 to 0.52)+2.94% per year(95% CI 2.14 to 3.73)+0.04% per year(95% CI -0.07 to 1.53)Absolute change in prescriptions in March 2020-46.3%+15.5%+10.7%Prescription trend after March 2020+2.11% per year(95% CI 0.52 to 3.70)+3.24% per year(95% CI 2.02 to 4.46)+0.64% per year(95% CI 0.38 to 0.90)Difference in trends post vs. pre-March 2020+2.33% per year(95% CI 0.51 to 4.17)P=0.014+0.30% per year(95% CI -1.03 to 1.63)P=0.65+0.60% per year(95% CI 0.31 to 0.90)P<0.001Figure 1.Temporal trends in prescriptions for ADA, RTX and TOC in England between January 2019 and November 2021. Monthly averages of prescriptions for combined disease indications are shown, standardised using WHO Defined Daily Doses.For ADA, the pre-pandemic trend of increasing prescriptions continued during the pandemic, with no differences in prescription trends seen in ITSA models (Table 1). A 22% decrease in ADA prescriptions was observed between September and October 2020, from 2,037,800 DDD to 1,587,500 DDD, respectively, before rebounding to above pre-pandemic levels. Prescriptions for TOC increased during the pandemic, driven primarily by a 76% increase in prescriptions between December 2020 and January 2021, from 241,800 DDD to 425,000 DDD, respectively.ConclusionPrescriptions for RTX in England halved during the early COVID-19 pandemic, and remain below pre-pandemic levels as of November 2021. This likely reflects concerns about RTX use and increased COVID-19 mortality and reduced vaccine efficacy.1,2 In contrast, prescriptions for ADA have continued to increase during the pandemic, while prescriptions for TOC surged in December 2020, coinciding with the more widespread use of TOC for the treatment of severe COVID-19.References[1]Strangfeld A, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930-942[2]Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatol. 2021 Dec 23Disclosure of InterestsMark Russell Speakers bureau: Lilly; Menarini, Sathiyaa Balachandran: None declared, Sam Norton: None declared, Edward Alveyn: None declared, Deepak Nagra: None declared, Maryam Adas: None declared, James Galloway Speakers bureau: Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi and UCB
Collapse
|
2
|
POS0285 SUB-STANDARD CARE FOR PATIENTS WITH GOUT, DESPITE UPDATED GUIDELINES: A UK-WIDE, POPULATION-BASED COHORT STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundTreat-to-target urate-lowering therapy (ULT) is highly effective at preventing flares and improving quality of life for patients with gout.1 However, in 2012, only 27% of patients with gout in UK primary care received prescriptions for ULT within 12 months of diagnosis.2 Since then, EULAR and BSR gout management guidelines have been updated, to recommend that all patients with gout should have ULT discussed and offered to them, with uptitration of dosing until target urate levels are achieved. We investigated whether gout management has improved in recent years.ObjectivesTo assess temporal trends in the initiation of ULT and attainment of serum urate targets following new gout diagnoses in UK primary care from 2004 to 2020.MethodsThe Clinical Practice Research Datalink (CPRD) Gold database was used to assess the management of patients with index diagnostic codes for gout in UK primary care between January 2004 and October 2020. We analysed the proportion of patients with the following outcomes within 12 months of diagnosis: i) initiation of ULT (allopurinol, febuxostat, benzbromarone, probenecid or sulfinpyrazone); ii) serum urate ≤360 µmol/L; iii) serum urate ≤300 µmol/L; iv) treat-to-target urate monitoring (defined as two or more serum urate levels performed within 12 months of diagnosis and/or one or more urate ≤300 µmol/L). Interrupted time-series analyses (ITSA) were used to estimate the impact of updated EULAR and BSR gout management guidelines on these outcomes. Multivariate logistic regression was used to analyse predictors of ULT prescription and target attainment following new gout diagnoses.Results129,972 patients had index gout diagnoses between January 2004 and October 2020, of whom only 37,529 (28.9%) had ULT initiated within 12 months of diagnosis. ULT initiation improved modestly over the study period, from 26.8% for those diagnosed in 2004 to 36.6% in 2019, decreasing to 34.7% in 2020 (Figure 1). Of patients diagnosed in 2020 who had a serum urate performed within 12 months of diagnosis, 36.0% attained a urate ≤360 µmol/L, while 17.1% attained a urate ≤300 µmol/L. Of all participants, 18.9% received treat-to-target urate monitoring. In ITSA models, no statistically significant improvements in ULT prescription or urate target attainment were observed after publication of updated EULAR (2016) or BSR (2017) gout management guidelines, relative to before publication of these guidelines. In multivariate logistic regression models, comorbidities including chronic kidney disease, heart failure and obesity, and diuretic use were associated with increased odds of ULT initiation but decreased odds of attaining target urate levels by 12 months.Figure 1.Proportion of patients newly diagnosed with gout who: i) were initiated on urate-lowering therapy (ULT) within 12 months of diagnosis (black line); ii) had a serum urate performed and attained a level ≤360 µmol/L (light blue) or ≤300 µmol/L (dark blue) within 12 months of diagnosis.ConclusionIn this UK-wide study, we demonstrate that the initiation of ULT and attainment of serum urate targets following new gout diagnoses remain poor, despite the introduction of updated management guidelines. If the evidence-practice gap in gout management is to be bridged successfully, strategies to implement best practice gout care are urgently needed.References[1]Doherty M, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018;392(10156):1403-12[2]Kuo CF, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74(4):661-7AcknowledgementsThis work is independent research supported by the National Institute for Health Research (NIHR) Doctoral Fellowship, Dr Mark Russell, NIHR300967. This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency.Disclosure of InterestsMark Russell Speakers bureau: Lilly; Menarini, Andrew Rutherford: None declared, Benjamin Ellis: None declared, Sam Norton: None declared, Abdel Douiri: None declared, Martin Gulliford: None declared, Andrew Cope: None declared, James Galloway Speakers bureau: Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi and UCB
Collapse
|
3
|
POS0504 LOW SOCIAL SUPPORT, WORSE FINANCIAL STATUS AND LIMITED PHYSICAL ACTIVITY AT RHEUMATOID ARTHRITIS ONSET PREDICTS EXCESS DISABILITY OVER 10 YEARS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPrevious research has identified trajectory groups of people with rheumatoid arthritis (RA) characterised by excess disability (with respect to inflammation)1. These excess disability trajectories were relatively fixed from symptom onset, indicating that sociodemographic and lifestyle factors prior to onset may partially determine the disability trajectories of people with RA, potentially mediated by patient reported outcomes (PROMs).ObjectivesTo (i) investigate the relationship between social support, financial status and lifestyle factors and excess disability group membership in RA, and (ii) evaluate the mediating effect of pain, fatigue, anxiety and depression on this relationship.MethodsData came from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) study, a prospective cohort from 14 centres across France. Inclusion criteria were: >2 swollen joints for 6 weeks-6 months, certain / possible diagnosis of RA, aged 18-70 years, and no disease modifying treatments or glucocorticoids for >2 weeks. A previous study applying trajectory analysis to the 10-year disability and inflammation scores of the ESPOIR participants identified pairs of trajectories characterised by similar inflammation but different disability1. For the current analysis, those in the higher disability trajectories of each pair were allocated into the “excess disability” group. At baseline, participants reported demographics, patient reported outcomes (pain / fatigue visual analogue scales; anxiety / depression: Arthritis Impact Measurement Scales), social support (availability of financial and accommodation support, family contact, married / co-habiting), financial status (personal and family income, job status and level, home owner, ability to go to the cinema/shows / go on holiday) and lifestyle factors (smoking, alcohol, body mass index [BMI; from height and weight], physical activity). Structural equation modelling was used to combine the social support and financial status data into latent variables, and then assess the direct and indirect (mediated by PROMs) effects of these variables as well as lifestyle factors on excess disability (adjusted for age and gender).ResultsIn total, 538 people with RA were included (mean [standard deviation] age: 48.3 [12.2] years; 79.2% women), 200 (37.2%) of whom had excess disability over 10 years. The excess disability group were older, included more women, and had worse PROMs at baseline compared with the no excess disability group (Table 1). Less social support (β 0.17, 95% CI 0.08, 0.26) and worse financial status (β 0.30, 95% CI 0.19, 0.41) both predicted excess disability group membership, as did lower physical activity (β 0.17, 95% CI 0.09, 0.25) (Figure 1), whereas smoking, alcohol and BMI at baseline did not. Only a small proportion of this effect was mediated by the PROMs (social support: 21%, financial status: 31%, physical activity: 28%; Figure 1).Table 1.Baseline characteristicsExcess disability,No excess disability,Mean (SD) / N (%)Mean (SD) / N (%)N200338Age, years50.4 (10.7)47.0 (12.8)Women, N(%)174 (87.0%)252 (74.6%)Symptom duration, months3.63 (2.02)3.36 (1.62)Pain VAS47.1 (27.4)37.0 (26.9)Fatigue VAS59.3 (27.2)46.5 (26.5)AIMS anxiety5.61 (2.25)4.71 (2.27)AIMS depression4.47 (2.24)3.47 (1.97)Health Assessment Questionnaire1.39 (0.64)0.93 (0.61)DAS28-2C4.04 (1.28)3.99 (1.34)AIMS = Arthritis Impact Measurement Scales, DAS28-2C = two-component Disease Activity Score, SD = standard deviation, VAS = visual analogue scaleConclusionDisability resulting from RA is a complex phenomenon, arising from more than just joint inflammation. This analysis indicates that lack of social support, financial instability and lower physical fitness at symptom onset may explain the excess disability associated with RA. As only a small portion of the effect is mediated by PROMs, health and social inequalities may need to be targeted directly by interventions.References[1]Gwinnutt et al (2021), Ann Rheum Dis, 80(Suppl 1)Disclosure of InterestsJames Gwinnutt: None declared, Sam Norton: None declared, Kimme Hyrich Speakers bureau: Abbvie, Grant/research support from: Bristol-Myers Squibb, Pfizer, Mark Lunt: None declared, Bernard Combe: None declared, Nathalie Rincheval: None declared, Adeline Ruyssen-Witrand: None declared, Bruno Fautrel: None declared, Suzanne Verstappen: None declared.
Collapse
|
4
|
POS0565 WORSE OUTCOMES LINKED TO ETHNICITY FOR EARLY INFLAMMATORY ARTHRITIS IN ENGLAND AND WALES: A NATIONAL COHORT STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients from ethnic minority backgrounds suffer considerable health inequality, with generally poorer health outcomes relative to the rest of the population.1 Further exploration of these differences is essential if we are to deliver the best care for all, and close the health gap for our patients.ObjectivesWe used the National Early Inflammatory Arthritis Audit (NEIAA) to assess variability in care quality and treatment outcomes across ethnicities for patients diagnosed with early inflammatory arthritis (EIA) in England and Wales.MethodsNEIAA is an observational cohort design. Data were from adult patients newly diagnosed with EIA, and seen by rheumatology in England and Wales between May 2018 and March 2020. Quality of care outcomes were assessed against six metrics contained within the National Institute for Health and Clinical Excellence (NICE) Quality Standard for Rheumatoid Arthritis.2 Clinical outcomes were measured using DAS28. Outcomes were compared between ethnic groups (White, Black, Asian, Mixed, Other), and adjusted for confounders (age, sex, smoking, comorbidity, seropositivity and disease severity at presentation) using Logistic regression models with multiple imputation for missing data.ResultsData for 35,807 eligible patients were analysed, of whom 30,643 (85.6%) were White and 5,164 (14.6%) were from ethnic minority backgrounds: 1,035 (2.8%) Black; 2,617 (7.3%) Asian; 238 (0.6%) Mixed; 1,274 (3.5%) Other. A total of 12,955 patients had confirmed EIA. Of those, 11,315 were White and 1,640 were from ethnic minority backgrounds: 314 (2.4%) Black; 927 (7.1%) Asian; 70 (0.5%) Mixed; 329 (2.5%) Other.Of 35,160 eligible patients who had data available, 14,803 (42.1%) were assessed by rheumatology within three weeks of referral. Of 9,900 EIA-eligible patients with data available, 5,642 (57.0%) started treatment within six weeks of referral. There were no significant differences in these outcomes by ethnicity. Ethnic minority patients did, however, have lower odds of disease remission at three months, relative to patients of White ethnicity (adjusted odds ratio 0.79; 95% CI: 0.65-0.96; p=0.02). This difference was due to lower odds of disease remission in Black and Asian patients, relative to White patients (Table 1). Ethnic minority patients were significantly less likely to receive initial treatment with methotrexate (0.68; 95% CI: 0.52-0.90; p=0.008) or with glucocorticoids (0.63, 95% CI: 0.49-0.80; p< 0.001).Table 1.Associations between ethnicity and disease remission at three months in EIA patientsModelOdds ratio95% CIP-valueUnadjustedAll ethnic minority0.76(0.62,0.93)0.01backgroundsBlack0.48(0.34,0.67)<0.001Asian0.74(0.59,0.93)0.01Mixed0.61(0.28,1.35)0.22Other1.09(0.71,1.68)0.67Age and sex-adjustedAll ethnic minority0.78(0.63,0.96)0.01backgroundsBlack0.49(0.35,0.69)0.00Asian0.75(0.60,0.94)0.01Mixed0.63(0.28,1.39)0.25Other1.11(0.71,1.71)0.63Fully-adjustedAll ethnic minority0.79(0.65,0.96)0.02backgroundsBlack0.57(0.41,0.79)0.001Asian0.76(0.62,0.93)0.009Mixed0.63(0.27,1.46)0.29Other1.04(0.71,1.54)0.80ConclusionThe results from this large cohort demonstrate that some minority ethnic groups are less likely to reach disease remission in the early months following an EIA diagnosis. Our results are not explained by delays in referral or treatment. Intitial treatment strategies varied across ethnic groups. These data highlight the need for investigation into the possible drivers of these inequitable outcomes and reappraisal of EIA management pathways.References[1]Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126(12):1089-98.[2]NICE quality standard for rheumatoid arthritis in over 16s. Nice.org.uk. 2013 [cited 25 January 2022]. Available from: https://www.nice.org.uk/guidance/qs33/documents/previous-version-of-quality-standard.Disclosure of InterestsMaryam Adas: None declared, Sathiyaa Balachandran: None declared, Sam Norton: None declared, Edward Alveyn: None declared, Mark Russell Speakers bureau: Has received speaker fees and educational grants from Janssen, Lilly, Menarini, Pfizer and UCB, Tom Esterine Speakers bureau: Patient review of P.I.S and consent form into lay language for KCL that was linked to Pharma company., Paul Amlani-Hatcher: None declared, Sarah Oyebanjo: None declared, Heidi Lempp: None declared, Jo Ledingham: None declared, Kanta Kumar Speakers bureau: Has received training form Pfizer and speaker fees 2021 from Janssen., Paid instructor for: Has received training form Pfizer, James Galloway Speakers bureau: Has received honoraria from AbbVie, Celgene, Chugai, Gilead, Janssen, Eli Lilly, Pfizer, Roche and UCB., Shirish Dubey: None declared.
Collapse
|
5
|
P104 Exploring the value of annual chest radiographs in people with cystic fibrosis: an observational study from a single UK centre. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00437-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
OP0253 COVID-19 ADMISSIONS AND MORTALITY IN PATIENTS WITH EARLY INFLAMMATORY ARTHRITIS: RESULTS FROM A NATIONAL COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThere has been a major concern about the impact of COVID-19 in patients with inflammatory arthritis during the pandemic, with recommendations from governments for patients to shield.ObjectivesOur aim was to describe the risk factors for COVID-19 hospitalisation and mortality amongst patients recruited to the National Early Inflammatory Arthritis Audit (NEIAA) in England.MethodsAn observational cohort study design was used. The population included adults in England with new diagnoses of inflammatory arthritis between May 2018 and March 2021 who enrolled in NEIAA. The outcomes were hospitalisation due to COVID-19 (primary admission reason or nosocomial acquisition) and death due to COVID-19 (COVID-19 stated on a death certificate), identified via linkage with secondary care records. Hazard ratios were calculated using Cox proportional hazards models, with adjustment for patient factors (age, gender, smoking status, and comorbidity) and disease factors (seropositivity, 28-joint disease activity score, patient-reported disability (HAQ), and functional impact (MSK-HQ)) recorded at baseline. Individuals were considered at risk from the date of diagnosis or February 2020 (whichever was later) and censored at a COVID-19 event, death or May 2021 (whichever was sooner).Results14,127 patients were included. The mean age was 57 years; 62% were female; 19% were current smokers, while 29% were ex-smokers. The frequency of comorbidities at baseline were: hypertension (19%), diabetes mellitus (9%), and lung disease (9%). Overall, 20% had two or more comorbidities. Rheumatoid factor or CCP antibodies were positive in 56%. At presentation, mean scores for DAS28 were 4.6 (+/- 1.5), 1.1 (+/- 0.7) for HAQ, and 25 (+/- 11) for MSK-HQ. Initial DMARD therapy was known for 13,682/14,127 patients: methotrexate was the most common (54%), followed by hydroxychloroquine (23%), and sulfasalazine (11%).There were 143 COVID-19 hospital admissions and 47 deaths, corresponding to incidence rates per 100 person-years for hospitalisation: 0.94 [95% CI: 0.79-1.10] and death: 0.31 [95% CI: 0.23-0.41]. Increasing age, male gender, diabetes, hypertension, lung disease and smoking status all predicted COVID-19 hospitalisation and death. Higher baseline DAS28 predicted COVID-19 hospitalisation (HR 1.24 [95% CI: 1.10-1.39]) and mortality (HR 1.33 [95% CI: 1.09-1.63]). Higher HAQ predicted both COVID-19 hospitalisation and death. Seropositivity was not a significant predictor of any COVID-19 event, nor was MSK-HQ. In unadjusted models, corticosteroids associated with COVID-19 death (HR 2.29 [95% CI: 1.02-5.13], and sulfasalazine monotherapy associated with COVID-19 hospitalisation (HR 1.93 [95% CI: 1.04-3.56]. In adjusted models, associations for corticosteroids and sulfasalazine were no longer significant. Only age, smoking status, and comorbidities independently predicted COVID-19 events.ConclusionThe burden of COVID-19 amongst early arthritis patients was substantial during the pandemic, with concerns about the use of csDMARDs and corticosteroids.1,2 Patient characteristics and rheumatoid disease severity at diagnosis appear to be the more important predictors of COVID-19 events than initial treatment strategy. An important limitation is that we have not looked at treatment changes over time, and must acknowledge that many patients, especially those recruited in 2019, may have changed therapy prior to the pandemic.References[1]Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases. 2021;80(7):930-942.[2]D’Silva KM, Wallace ZS. COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Curr Rheumatol Rep. 2021;23(5):28-28.Disclosure of InterestsMaryam Adas: None declared, Mark Russell Speakers bureau: has received speaker fees and educational grants from Janssen, Lilly, Menarini, Pfizer and UCB., Emma Cook: None declared, Edward Alveyn: None declared, Sarah Oyebanjo: None declared, Paul Amlani-Hatcher: None declared, Jo Ledingham: None declared, Sam Norton: None declared, James Galloway Speakers bureau: Has received honoraria from AbbVie, Celgene, Chugai, Gilead, Janssen, Eli Lilly, Pfizer, Roche and UCB
Collapse
|
7
|
Dysregulation of immune cell and cytokine signaling correlates with clinical outcomes in myelodysplastic syndrome (MDS). Eur J Haematol 2021; 108:342-353. [PMID: 34963023 DOI: 10.1111/ejh.13742] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 12/19/2021] [Accepted: 12/21/2021] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis. Although hypomethylating agents (HMA) have improved survival in higher-risk MDS, most patients eventually succumb to progressive disease. Utilizing samples collected prospectively from three MDS clinical trials, we analyzed genetic and immunological biomarkers and correlated them with clinical outcomes. METHODS 154 samples were analyzed from 133 de novo MDS patients for T-cell and myeloid cell immunophenotyping and gene expression analysis. Treatments were with HMA or immunomodulatory drug (IMiD) alone or in combination. RESULTS We observed differences in immune cell subsets between lower and higher risk IPSS groups with NKT cells, MDSCs, intermediate-proinflammatory and non-classical monocytes being higher in the latter group while naïve CD4+ T-cells were reduced. Intermediate-proinflammatory monocytes were increased in non-responders and those failing to achieve at least a hematological improvement. Pro-inflammatory NKT cells were increased at diagnosis for patients failing to derive clinical benefit after 12 months of treatment. Gene expression analysis of paired bone marrow (BM) colony-forming units (CFUs) from diagnosis and 4 cycles post-treatment confirmed that genes involved in cytokine signaling were downregulated in C4 normal colonies. CONCLUSIONS These findings support the central roles of dysregulation in innate immunity and inflammatory signaling in the pathogenesis of MDS which correlated with clinical outcomes post-treatment.
Collapse
|
8
|
Developing and adapting a patient-centered communication tool (UR-GOAL) for older patients with acute myeloid leukemia (AML) and their oncologist. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00358-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Ultraviolet exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour. Br J Dermatol 2021; 186:713-720. [PMID: 34783007 PMCID: PMC9306996 DOI: 10.1111/bjd.20899] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/13/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND In Xeroderma Pigmentosum (XP), the main means of preventing skin and eye cancers is extreme protection against ultraviolet radiation (UVR). Protection is most important for the face. OBJECTIVES We aimed to assess how well patients with XP adhere to medical advice to protect against UVR by objectively estimating the mean daily dose of UVR to the face. METHODS We objectively estimated the UVR dose to the face in 36 XP patients and 25 healthy individuals over 3 weeks in the summer. We used a new methodology which combined UVR dose measurements from a wrist-worn dosimeter with an activity diary record of face photoprotection behaviour for each 15 minute period spent outside. A protection factor was associated with each behaviour, and the data analysed using a negative binomial mixed-effects model. RESULTS The mean daily UVR dose (weighted for DNA damage capacity) to the face in the XP patients was 0.13 Standard Erythemal Doses (SED) (mean in healthy individuals = 0.51 SED). There was wide variation between patients (range <0.01 - 0.48 SED/day). Self-caring adult patients had a very similar UV dose to the face to cared-for patients (0.13 vs 0.12 SED/day) despite photoprotecting much more poorly when outside, because the self-caring adults were outside in daylight much less. CONCLUSIONS Photoprotection behaviour varies widely within the XP group indicating that non-adherence to photoprotection advice is a significant issue. Timing and duration of going outside are as important as photoprotective measures taken when outside, to determine the UVR exposure to the face. This new methodology will be of value in identifying the sources of UVR exposure in other conditions where facial UV exposure is a key outcome, particularly in patients with multiple non-melanoma skin cancers.
Collapse
|
10
|
The Paediatric Renal Transplant Recipient: A retrospective review of the changing trends of transplantation in Ireland. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00201-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
A cross sectional sample study of pregnancy and renal outcomes after renal transplant at the National Kidney Transplant Service. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00200-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol 2021; 185:80-90. [PMID: 33368145 PMCID: PMC9214088 DOI: 10.1111/bjd.19755] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/19/2020] [Indexed: 01/10/2023]
Abstract
BACKGROUND Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. OBJECTIVES We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. METHODS Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. RESULTS Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35-1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23-1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05-1·24), obesity (OR 1·37, 95% CI 1·23-1·54), comorbidity burden (OR 1·43, 95% CI 1·15-1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27-1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36-1·80). Modest differences in the proportion shielding were observed across nations. CONCLUSIONS Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
Collapse
|
13
|
Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol 2021; 35:e636-e640. [PMID: 34145643 PMCID: PMC8447018 DOI: 10.1111/jdv.17450] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
POS0959 DIAGNOSTIC DELAY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE NATIONAL EARLY INFLAMMATORY ARTHRITIS AUDIT. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Diagnostic delay is a significant problem in axial spondyloarthritis (axSpA), and there is a growing body of evidence showing that delayed axSpA diagnosis is associated with worse clinical, humanistic and economic outcomes.1 International guidelines have been published to inform referral pathways and improve standards of care for patients with axSpA.2,3Objectives:To describe the sociodemographic and clinical characteristics of newly-referred patients with axSpA in England and Wales in the National Early Inflammatory Arthritis Audit (NEIAA), with rheumatoid arthritis (RA) and mechanical back pain (MBP) as comparators.Methods:The NEIAA captures data on all new patients over the age of 16 referred with suspected inflammatory arthritis to rheumatology departments in England and Wales.4 We describe baseline sociodemographic and clinical characteristics of axSpA patients (n=784) recruited to the NEIAA between May 2018 and March 2020, compared with RA (n=9,270) and MBP (n=370) during the same period.Results:Symptom duration prior to initial rheumatology assessment was significantly longer in axSpA than RA patients (p<0.001), and non-significantly longer in axSpA than MBP patients (p=0.062): 79.7% of axSpA patients had symptom durations of >6 months, compared to 33.7% of RA patients and 76.0% of MBP patients; 32.6% of axSpA patients had symptom durations of >5 years, compared to 3.5% of RA patients and 24.6% of MBP patients (Figure 1A). Following referral, median time to initial rheumatology assessment was longer for axSpA than RA patients (36 vs. 24 days; p<0.001), and similar to MBP patients (39 days; p=0.30). The proportion of axSpA patients assessed within 3 weeks of referral increased from 26.7% in May 2018 to 34.7% in March 2020; compared to an increase from 38.2% to 54.5% for RA patients (Figure 1B). A large majority of axSpA referrals originated from primary care (72.4%) or musculoskeletal triage services (14.1%), with relatively few referrals from gastroenterology (1.9%), ophthalmology (1.4%) or dermatology (0.4%).Of the subset of patients with peripheral arthritis requiring EIA pathway follow-up, fewer axSpA than RA patients had disease education provided (77.5% vs. 97.8%; p<0.001), and RA patients reported a better understanding of their condition (p<0.001). HAQ-DI scores were lower at baseline in axSpA EIA patients than RA EIA patients (0.8 vs 1.1, respectively; p=0.004), whereas baseline Musculoskeletal Health Questionnaire (MSK-HQ) scores were similar (25 vs. 24, respectively; p=0.49). The burden of disease was substantial across the 14 domains comprising MSK-HQ in both axSpA and RA (Figure 1C).Conclusion:We have shown that diagnostic delay remains a major challenge in axSpA, despite improved disease understanding and updated referral guidelines. Patient education is an unmet need in axSpA, highlighting the need for specialist clinics. MSK-HQ scores demonstrated that the functional impact of axSpA is no less than for RA, whereas HAQ-DI may underrepresent disability in axSpA.References:[1]Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review. Rheumatol Ther. 2020;7:65-87.[2]NICE. Spondyloarthritis in over 16s: diagnosis and management. 2017.[3]van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91.[4]British Society for Rheumatology. National Early Inflammatory Arthritis Audit (NEIAA) Second Annual Report. 2021.Acknowledgements:The National Early Inflammatory Arthritis Audit is commissioned by the Healthcare Quality Improvement Partnership, funded by NHS England and Improvement, and the Welsh Government, and carried out by the British Society for Rheumatology, King’s College London and Net Solving.Disclosure of Interests:Mark Russell Grant/research support from: UCB, Pfizer, Fiona Coath: None declared, Mark Yates Grant/research support from: UCB, Abbvie, Katie Bechman: None declared, Sam Norton: None declared, James Galloway Grant/research support from: Abbvie, Celgene, Chugai, Gilead, Janssen, Lilly, Pfizer, Roche, UCB, Jo Ledingham: None declared, Raj Sengupta Grant/research support from: AbbVie, Biogen, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, UCB, Karl Gaffney Grant/research support from: AbbVie, Biogen, Cellgene, Celltrion, Janssen, Lilly, Novartis, Pfizer, Roche, UCB.
Collapse
|
15
|
OP0183 IDENTIFICATION OF A SUBGROUP OF PEOPLE WITH RHEUMATOID ARTHRITIS CHARACTERISED BY HIGH DISABILITY OVER 10 YEARS, DESPITE LOW INFLAMMATION: RESULTS FROM TWO EUROPEAN PROSPECTIVE COHORT STUDIES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Long-term studies in rheumatoid arthritis (RA) have reported low inflammation yet high disability over time. It is important to determine which factors are driving this disparity, so appropriate interventions can be used to reduce this gap.Objectives:To identify a subgroup of people with RA with low inflammation yet high disability over 10 years, and describe their characteristics.Methods:Data came from two cohorts of inflammatory arthritis with regular assessments over 10 years: the Norfolk Arthritis Register (NOAR, inclusion: ≥2 swollen joints for ≥4 weeks) from the UK and the Etude et Suivi des Polyarthrites Indifférenciées Récentes study (ESPOIR, inclusion: early RA) from France. Participants provided demographic data and completed patient reported outcomes (PROs, including the Health Assessment Questionnaire [HAQ]). The 2-component Disease Activity Score (DAS28-2C)1, a measure of inflammation, was calculated from swollen joint counts and C-reactive protein level. Inclusion criteria for this analyis: <2 years baseline symptom duration; HAQ and DAS28-2C at baseline and one other follow-up; recruited after 1/1/2000. HAQ and DAS28-2C were modelled simultaneously using a multivariate group-based trajectory model, to identify groups of participants with similar trajectories of HAQ and DAS28-2C over 10 years. Baseline demographics and PROs were compared between the trajectory groups using logistic regression. Analyses performed separately in NOAR and ESPOIR.Results:1001 NOAR and 767 ESPOIR participants were included. In both cohorts, a four group trajectory model had the best fit (Figure). Two subgroups were identified in each cohort that demonstrated the hypothesised relationship: similar DAS28-2C but differing HAQ scores (red trajectories in Figure), titled “High HAQ” and “Low HAQ” (mean difference in HAQ over follow-up [95% confidence interval (CI)]: NOAR 0.76 [0.73, 0.80]; ESPOIR 0.89 [0.82, 0.96]). At baseline, the High HAQ groups in both NOAR and ESPOIR were older, had a higher proportion of women, and had higher levels of fatigue (NOAR: odds ratio [OR] 1.16 [95% CI 1.06, 1.28]; ESPOIR: OR 1.20 [95% CI 1.05, 1.36] [Table]) and pain (NOAR only).Table 1.Baseline characteristics / logistic regression analysisNOARESPOIRVariableLow HAQ trajectory, mean (SD)High HAQ trajectory, mean (SD)OR (95% CI)Low HAQ trajectory, mean (SD)High HAQ trajectory, mean (SD)OR (95% CI)N (%)343 (59%)239 (41%)-131 (55%)108 (45%)-Age, years54.9 (14.2)62.1 (13.8)1.07 (1.05, 1.08)47.8 (13.3)51.8 (11.2)1.04 (1.01, 1.06)Women, N (%)224 (65.3%)176 (73.6%)1.82 (1.12, 2.78)100 (76.3%)95 (88.0%)2.73 (1.20, 6.23)Symptom duration, months7.8 (5.1)8 (5.4)1.10 (0.98, 1.05)3.4 (1.8)3.6 (1.8)1.16 (0.98, 1.37)Current smoker, N (%)77 (22.4%)50 (20.9%)1.19 (0.71, 2.00)61 (46.6%)52 (48.1%)1.52 (0.82, 2.83)DAS28-2C3.14 (1.46)3.21 (1.56)-4.65 (1.31)4.41 (1.35)-HAQ0.8 (0.6)1.4 (0.5)-1.1 (0.6)1.6 (0.6)-Pain (0-10)3.7 (2.4)4.6 (2.5)1.16 (1.07, 1.26)4.1 (2.8)5.1 (2.6)1.07 (0.95, 1.20)Fatigue (0-10)4.3 (2.8)5.3 (2.5)1.16 (1.06, 1.28)5.0 (2.6)6.5 (2.5)1.20 (1.05, 1.36)AIMS anxiety3.99 (1.96)4.42 (1.99)1.06 (0.88, 1.29)4.9 (2.26)5.98 (2.25)1.10 (0.94, 1.29)AIMS depression2.85 (1.87)3.38 (1.87)1.10 (0.94, 1.29)3.96 (1.99)5.08 (2.32)1.12 (0.94, 1.33)RF+, N (%)142 (41.4%)106 (44.4%)0.94 (0.60, 1.46)79 (60.3%)50 (46.3%)0.77 (0.34, 1.75)Anti-CCP+, N (%)113 (32.9%)86 (36.0%)1.35 (0.84, 2.17)76 (58.0%)45 (41.7%)0.89 (0.39, 2.05)Conclusion:There is a group of people with RA with high levels of disability, despite low inflammation. These results underline the potential need for pain and fatigue management in people with RA, even when inflammation is low.References:[1]Hensor et al (2019). Rheumatology (Oxford) 58(8)Acknowledgements:Thanks to the participants of NOAR and ESPOIR and those working in the recruiting centresESPOIR Funding:An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years of the cohort study. Two additional grants from INSERM supported part of the biological database. The French Society of Rheumatology, Abbvie, Pfizer, Lilly and more recently Fresenius and Biogen supported the ESPOIR cohort study.Disclosure of Interests:James Gwinnutt Grant/research support from: Research grant from Bristol Myers Squibb unrelated to this project, Sam Norton Consultant of: Pfizer and AstraZeneca, Kimme Hyrich Consultant of: Abbvie, Grant/research support from: Pfizer and BMS, Mark Lunt: None declared, Bernard Combe: None declared, Nathalie Rincheval: None declared, Adeline Ruyssen-Witrand: None declared, Bruno Fautrel: None declared, Jacqueline Chipping: None declared, Alex MacGregor: None declared, Suzanne Verstappen: None declared
Collapse
|
16
|
POS0494 AN INVESTIGATION OF JOINT INFLAMMATION DEFINED BY COMPREHENSIVE ULTRASOUND ASSESSMENT AND PAIN SENSITISATION IN PATIENTS WITH ACTIVE RA. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Treat-to-target strategies have improved outcomes in patients with RA. Targets based on clinical assessments of tender (TJC) and swollen joints (SJC) were developed when most patients had active inflammatory disease. It is now recognised some patients have pain sensitisation often termed fibromyalgia (FM), making clinical assessment of inflammatory disease more complex. An indicator of pain sensitisation is the difference between TJC and SJC, an observation we described in a pilot study (1).Objectives:To study patients with RA to describe the relationships between enhanced clinical and patient-reported outcome measures (PROMS) and active inflammatory joint disease detected by comprehensive PDUS.Methods:158 sequential patients with RA with a DAS28ESR score >¬3.2 were enrolled from GSTT Rheumatology after informed consent. They were assessed by a rheumatologist for 66SJC, 68TJC, fibromyalgia tender points & physician global. Recorded PROMS were: patient global, widespread pain index (WPI), symptom severity score (somatic & fatigue), FACIT fatigue, HAQ, EQ5D QoL, GAD7, PHQ9 and PHQ15. All patients had a 44 joint US scored for PD and grey scale by the EULAR scale blind to all patient data. Data were recorded on MedSciNet and statistical analysis used STATA.Results:Patients meeting the ACR 2010 criteria for FM2(n=72) vs those that did not(n=86) had similar demographics. SJC and US doppler scores were higher in the non-FM group, whereas rheumatoid factor, DAS28 and PROMs were higher in the FM group. Analysis of group differences using multinomial logistic regression and subsequent regularised (lasso) logistic regression, showed the FM group related to higher 28TJC, FACIT-F and PHQ15, with the non-FM group related to higher 28SJC, logESR, and lower Differences in 28S/TJC, Physician Global and FACIT-F. Patients were divided into four groups based on presence or absence of at least one PDUS+ joint and FM criteria; -FM-PD, -FM+PD, +FM-PD and +FM+PD, data summarised Table 1. The -FM-PD and -FM+PD groups related to Physician Global and negatively related to FACIT-F, Difference in 28S/TJC, and PHQ15 (-FM-PD). The +FM-PD group related positively to FACIT-F, Difference 28S/TJC, PHQ15, and negatively to Physician Global with +FM+PD related to PHQ9, FACIT-F and DAS28ESR.TABLE 1.-FM -PD -FM +PD +FM -PD +FM +PD p-valueFemale34 (79%)33 (77%)35 (83%)22 (73%)0.77Total power doppler score0.0 (0.0-1.0)16.0 (10.0-25.0)0.0 (0.0-0.0)9.0 (8.0-20.0)<0.001Total gray scale score40.0(34.0-48.0)57.5(45.0-82.0)34.5(20.0-43.0)60.0(46.0-84.0)<0.001Total Swollen JC3.0 (1.0-5.0)6.0 (3.0-9.0)2.0 (0.0-5.0)5.5 (2.0-10.5)<0.001Total Tender5.5 (3.0-12.0)8.0 (4.0-11.0)13.0 (8.0-20.0)15.0 (8.0-20.0)<0.001Tender-Swollen JC Difference4.0 (0.0-8.0)2.0 (0.0-4.0)8.0 (4.0-18.0)5.5 (2.5-13.5)<0.001ESR mm/hour10.0 (8.0-16.0)14.0 (10.0-30.0)12.0 (7.0-23.0)19.5 (11.5-42.5)0.021Pain VAS50.0 (40.0-65.0)50.0 (30.0-60.0)60.0 (47.5-77.5)67.5 (55.0-80.0)<0.001Patient VAS50.0 (30.0-70.0)40.0 (30.0-70.0)60.0 (40.0-80.0)65.0 (50.0-80.0)0.006Physician VAS30.0 (20.0-50.0)50.0 (40.0-60.0)30.0 (20.0-40.0)50.0 (32.5-70.0)<0.001DAS28 (ESR)4.2 (3.7-4.9)4.7 (4.1-5.2)4.7 (3.9-5.8)5.6 (4.9-6.6)<0.001Conclusion:These data using comprehensive US assessment to detect inflammatory joint disease, demonstrate that active inflammation defined as at least 1PDUS+ joint, may account for disease activity in slightly less than half of unselected patients with RA with a DAS28ESR score >3.2. This study shows how frequently pain sensitisation accounts for symptoms and signs in RA. We suggest in addition to central sensitisation, often called FM, another group identified here as -FM-PD, may have pain from joint damage or peripheral pain sensitisation of joints, likely due to different mechanisms than central pain sensitisation.References:[1]Mian A et al, BMC Musculoskelet Disord. 2016;17: 404[2]Wolfe F et al, Arth Care & Res 2010; 62:600Disclosure of Interests:Khaldoun Chaabo: None declared, Estee Chan: None declared, Toby Garrood: None declared, Zoe Rutter-Locher: None declared, Alexandra Vincent: None declared, James Galloway Speakers bureau: Dr Galloway has received speaker fees / honoraria from Abbvie, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi and UCB, Sam Norton: None declared, Bruce Kirkham Speakers bureau: Professor Bruce Kirkham has received speaker fees / honoraria from Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer,and UCB., Grant/research support from: Professor Bruce Kirkham has received research support from Lilly, Novartis and UCB.Professor Bruce Kirkham has received speaker fees / honoraria from Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB.
Collapse
|
17
|
POS-029 PATTERNS OF AKI IN PATIENTS HOSPITALISED WITH COVID-19 DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC IN A LARGE UK TERTIARY CENTRE. Kidney Int Rep 2021. [PMCID: PMC8049682 DOI: 10.1016/j.ekir.2021.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
18
|
The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. Br J Dermatol 2020; 183:808-820. [PMID: 32034956 PMCID: PMC7687112 DOI: 10.1111/bjd.18943] [Citation(s) in RCA: 103] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/07/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND Scabies is a common parasitic skin condition that causes considerable morbidity globally. Clinical and epidemiological research for scabies has been limited by a lack of standardization of diagnostic methods. OBJECTIVES To develop consensus criteria for the diagnosis of common scabies that could be implemented in a variety of settings. METHODS Consensus diagnostic criteria were developed through a Delphi study with international experts. Detailed recommendations were collected from the expert panel to define the criteria features and guide their implementation. These comments were then combined with a comprehensive review of the available literature and the opinion of an expanded group of international experts to develop detailed, evidence-based definitions and diagnostic methods. RESULTS The 2020 International Alliance for the Control of Scabies (IACS) Consensus Criteria for the Diagnosis of Scabies include three levels of diagnostic certainty and eight subcategories. Confirmed scabies (level A) requires direct visualization of the mite or its products. Clinical scabies (level B) and suspected scabies (level C) rely on clinical assessment of signs and symptoms. Evidence-based, consensus methods for microscopy, visualization and clinical symptoms and signs were developed, along with a media library. CONCLUSIONS The 2020 IACS Criteria represent a pragmatic yet robust set of diagnostic features and methods. The criteria may be implemented in a range of research, public health and clinical settings by selecting the appropriate diagnostic levels and subcategories. These criteria may provide greater consistency and standardization for scabies diagnosis. Validation studies, development of training materials and development of survey methods are now required. What is already known about this topic? The diagnosis of scabies is limited by the lack of accurate, objective tests. Microscopy of skin scrapings can confirm the diagnosis, but it is insensitive, invasive and often impractical. Diagnosis usually relies on clinical assessment, although visualization using dermoscopy is becoming increasingly common. These diagnostic methods have not been standardized, hampering the interpretation of findings from clinical research and epidemiological surveys, and the development of scabies control strategies. What does this study add? International consensus diagnostic criteria for common scabies were developed through a Delphi study with global experts. The 2020 International Alliance for the Control of Scabies (IACS) Criteria categorize diagnosis at three levels of diagnostic certainty (confirmed, clinical and suspected scabies) and eight subcategories, and can be adapted to a range of research and public health settings. Detailed definitions and figures are included to aid training and implementation. The 2020 IACS Criteria may facilitate the standardization of scabies diagnosis.
Collapse
|
19
|
The Effect of a JJ Stent on Sexual Function and Satisfaction. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35276-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
SAT0038 CHANGES IN ILLNESS PERCEPTIONS IN PEOPLE WITH RHEUMATOID ARTHRITIS OVER THE FIRST YEAR OF TREATMENT WITH METHOTREXATE. Ann Rheum Dis 2020. [DOI: 10.1136/annrhveumdis-2020-eular.1960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Illness perceptions at treatment onset are known to be important predictors of treatment response in rheumatoid arthritis (RA). Yet it is unknown how these perceptions change over time after the initiation of treatment, or which factors are associated with changing perceptions.Objectives:To identify groups of patients with early RA who have similar changes in illness perceptions over the first year following treatment, and assess predictors of these changes.Methods:Patients starting methotrexate (MTX) for the first time were recruited to the Rheumatoid Arthritis Medication Study (RAMS), a one-year prospective cohort. The DAS28 was calculated and patients completed a questionnaire at baseline and 12 months, reporting demographics and completing the HAQ, the Hospital Anxiety and Depression Scale (HADS), pain and fatigue visual analogue scales (VAS) and the Brief Illness Perception Questionnaire (B-IPQ). The B-IPQ consists of eight Likert scales: five represent cognitive illness perceptions (B-IPQ1-5), two represent emotional representations (B-IPQ6 & 8) and one represents illness comprehensibility (B-IPQ7). Change in illness perceptions and EULAR response were calculated over 12 months in those with data at both timepoints. Latent profile analysis was used to identify profiles of patients with similar changes in illness perceptions. Candidate predictors of profile membership were assessed using logistic regression. The association between profile and EULAR response was assessed using ordered logistic regression.Results:In total 1188 patients were included (mean [SD] age: 59.8 [12.7], 781 [65.7%] women). On average, illness perceptions for the whole cohort improved over 12 months, other than patients’ perception of longevity of arthritis (B-IPQ2) and of treatment helpfulness (B-IPQ4). Three profiles were identified: Small Improvers (N=900), Small Deteriorators (N=78) and Large Improvers (N=210) (Figure). Small Improvers improved on all B-IPQ items other than their perception of longevity of arthritis (B-IPQ2) and of treatment helpfulness (B-IPQ4). All B-IPQ items improved in the Large Improvers group to a greater extent than the Small Improvers, other than arthritis longevity (B-IPQ2). The perceptions of Small Deteriorators all worsened, other than arthritis comprehensibility (B-IPQ7). Higher baseline pain was associated with greater odds of being in both the Small Deteriorators and Large Improvers compared to Small Improvers (Small Deteriorators: OR 1.56 per standard deviation (SD) increase in pain [95% CI 1.11, 2.18]; Large Improvers: OR 1.46 per SD increase in pain [95% CI 1.15, 1.85]). Odds of better EULAR response were greater in the Large Improvers (OR 4.37 [95% CI 3.01, 6.33]) and worse in the Small Deteriorators (OR 0.50 [95% CI 0.29, 0.87]) compared to Small Improvers.Conclusion:In general, illness perceptions improved over the first year of MTX treatment and improvements were associated with better treatment response. Worsening illness perceptions may be driven by poor treatment response. These poor illness perceptions at follow-up may compound poor treatment response in the future. Greater understanding of patients’ initial and subsequent illness perceptions is crucial, given the association with treatment response.Figure:Disclosure of Interests:James Gwinnutt Grant/research support from: BMS, Sam Norton: None declared, Kimme Hyrich Grant/research support from: Pfizer, UCB, BMS, Speakers bureau: Abbvie, Mark Lunt: None declared, Anne Barton Consultant of: AbbVie, Lis Cordingley Grant/research support from: Unrestricted award from Pfizer unrelated to current abstract, Speakers bureau: Janssen, AbbVie, Celgene, Sanofi, Eli Lilly, Novartis all unrelated to current abstract, Suzanne Verstappen Grant/research support from: BMS, Consultant of: Celltrion, Speakers bureau: Pfizer
Collapse
|
21
|
Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. Semin Arthritis Rheum 2019; 50:209-219. [PMID: 31521376 DOI: 10.1016/j.semarthrit.2019.08.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 08/09/2019] [Accepted: 08/21/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVES To conduct a systematic review and longitudinal meta-analysis of early rheumatoid arthritis (RA) cohorts with long-term data on pain, fatigue or mental well-being. METHODS Searches using PUBMED, EMBASE and PyscInfo were performed to identify all early RA cohorts with longitudinal measures of pain, fatigue or mental well-being, along with clinical measures. Using longitudinal meta-analyses, the progression of each outcome over the first 60-months was estimated. Cohorts were stratified based on the median recruitment year to investigate secular trends in disease progression. RESULTS Of 7,319 papers identified, 75 met the inclusion criteria and 46 cohorts from 41 publications provided sufficient data on 18,046 patients for meta-analysis. The Disease Activity Scores (DAS28) and the Short-Form 36 (SF-36) Physical Component Score (PCS) indicated that post-2002 cohorts had statistically significant improvements over the first 60-months compared to pre-2002 cohorts, with standardised mean differences (SMD) of 0.86 (95% Confidence Intervals 0.34 to 1.37) and 0.76 (95% CI 0.25 to 1.27) respectively at month-60. However, post-2002 cohorts indicated statistically non-significant improvements in pain, fatigue, functional disability and SF-36 Mental Component Score (MCS) compared to pre-2002 cohorts, with SMD of 0.24 (95% CI -0.25 to 0.74), 0.38 (95% CI -0.11 to 0.88), 0.34 (95% CI -0.15-0.84) and -0.08 (95% CI -0.41 to 0.58) at month-60 respectively. CONCLUSIONS Recent cohorts indicate improved levels of disease activity and physical quality of life, however this has not translated into similar improvements in levels of pain, fatigue and functional disability by 60-months.
Collapse
|
22
|
Evaluating the suitability of an English saddle for a horse and rider combination. EQUINE VET EDUC 2019. [DOI: 10.1111/eve.13158] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation? Clin Exp Immunol 2019; 197:308-318. [PMID: 30762873 DOI: 10.1111/cei.13276] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/06/2019] [Indexed: 12/17/2022] Open
Abstract
Depressive symptoms are reported by more than 20% of people with inflammatory bowel disease (IBD), while sleep difficulties and fatigue are even more common. Co-morbid depressive symptoms predict a poor IBD course, including increased risk of relapse and surgery, which is inconsistently improved by psychological treatments. Rather than being distinct systems, there is compelling evidence for bidirectional communication between gut and brain, driven by neural, metabolic, endocrine and inflammatory mediators. An emerging concept is that depressive symptoms may be mechanistically linked to excess inflammation and dysregulation of the gut-brain axis. Given the close link between the intestinal microbiota and host immune responses, patients prone to shifts in their intestinal microbiome, including smokers, those with poor diet and early life stress, may be exposed to exaggerated immune responses. Excess inflammation is associated with brain changes (depressive symptoms, fatigue, sleep difficulties) and worsening gastrointestinal symptoms, which are exacerbated by psychological distress. Equally, treatments both for depressive symptoms and IBD provide opportunities to break this cycle by reducing the causes and effects of inflammation. As well as addressing potential risk factors such as smoking and diet, treatments to alter the microbiome may reduce depressive symptoms. Observational evidence suggests that anti-inflammatory treatments for IBD may improve co-morbid depressive symptoms correlating with reduction in inflammation. With a growing range of treatments targeting inflammation centrally, peripherally and in the gut, IBD provides a unique model to understand the interplay between brain and gut in the pathogenesis of depressive symptoms, both in IBD and in the whole population.
Collapse
|
24
|
Physiotherapy informed by Acceptance and Commitment Therapy (PACT) for people with chronic low back pain: a randomised controlled trial. Physiotherapy 2019. [DOI: 10.1016/j.physio.2018.11.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. Arthritis Care Res (Hoboken) 2018; 70:1257-1262. [DOI: 10.1002/acr.23468] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2017] [Accepted: 11/07/2017] [Indexed: 11/10/2022]
|
26
|
A dog's life: an unfamiliar and lethal side effect of topical 5-fluorouracil. Clin Exp Dermatol 2018; 43:732. [DOI: 10.1111/ced.13537] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/18/2017] [Indexed: 11/30/2022]
|
27
|
Trajectories of alcohol use in the UK military and associations with mental health. Addict Behav 2017; 75:130-137. [PMID: 28734152 DOI: 10.1016/j.addbeh.2017.07.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 05/28/2017] [Accepted: 07/10/2017] [Indexed: 12/14/2022]
Abstract
INTRODUCTION There are higher levels of alcohol misuse in the military compared to the general population. Yet there is a dearth of research in military populations on the longitudinal patterns of alcohol use. This study aims to identify group trajectories of alcohol consumption in the UK military and to identify associations with childhood adversity, deployment history and mental disorder. METHODS Data on weekly alcohol consumption across an eight year period and three phases of a UK military cohort study (n=667) were examined using growth mixture modelling. RESULTS Five alcohol trajectory classes were identified: mid-average drinkers (55%), abstainers (4%), low level drinkers (19%), decreasing drinkers (3%) and heavy drinkers (19%). Alcohol consumption remained stable over the three periods in all classes, other than in the small decreasing trajectory class. Individuals in the heavy drinking class were more likely to have deployed to Iraq. Abstainers and heavy drinkers were more likely to report post-traumatic stress disorders at baseline compared to average drinkers. CONCLUSIONS Heavy drinkers in the UK military did not change their drinking pattern over a period of eight years. This highlights the need to develop effective preventive programmes to lessen the physical and psychological consequences of long-term heavy alcohol use. Individuals with a mental health problem appeared more likely to either be drinking at a high level or to be abstaining from use.
Collapse
|
28
|
The impact of a structured clinical training course on interns' self-reported confidence with core clinical urology skills. Ir J Med Sci 2017; 187:255-260. [PMID: 28474236 DOI: 10.1007/s11845-017-1616-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 04/04/2017] [Indexed: 11/25/2022]
Abstract
BACKGROUND Undergraduate training in core urology skills is lacking in many Irish training programmes. AIMS Our aim was to assess newly qualified doctors' experience and confidence with core urological competencies. METHODS A questionnaire survey covering exposure to urology and confidence with core clinical skills was circulated to all candidates. The group then attended a skills course covering male/female catheterisation, insertion of three-way catheters, bladder irrigation and management of long-term suprapubic catheters. The groups were re-surveyed following the course. RESULTS Forty-five interns completed the pre-course questionnaire (group 1) and 27 interns completed the post-course questionnaire (group 2). 24/45 (53%) had no experience of catheter insertion on a patient during their undergraduate training. 26/45 (58%) were unsupervised during their first catheter insertion. 12/45 (27%) had inserted a female catheter. 18/45 (40%) had inserted a three-way catheter. 12/45 (27%) had changed a suprapubic catheter. 40/45 (89%) in group 1 reported 'good' or 'excellent' confidence with male urinary catheterisation, compared to 25/27 (92.5%) in group 2. 18/45 (40%) in group 1 reported 'none' or 'poor' confidence with female catheterisation, compared to 7/27 (26%) in group 2. 22/45 (49%) in group 1 reported 'none' or 'poor' confidence with insertion of three-way catheters, compared to 2/27 (7%) in group 2. 32/45 (71%) in group 1 reported 'none' or 'poor' confidence in changing long-term suprapubic catheters, falling to 3/27 (11%) in group 2. CONCLUSION This study raises concerns about newly qualified doctors' practical experience in urology. We suggest that this course improves knowledge and confidence with practical urology skills and should be incorporated into intern induction.
Collapse
|
29
|
Affect systems, changes in body mass index, disordered eating and stress: an 18-month longitudinal study in women. Health Psychol Behav Med 2017; 5:214-228. [PMID: 28553564 PMCID: PMC5425623 DOI: 10.1080/21642850.2017.1316667] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 04/04/2017] [Indexed: 11/02/2022] Open
Abstract
Background: Evidence suggests that stress plays a role in changes in body weight and disordered eating. The present study examined the effect of mood, affect systems (attachment and social rank) and affect regulatory processes (self-criticism, self-reassurance) on the stress process and how this impacts on changes in weight and disordered eating. Methods: A large sample of women participated in a community-based prospective, longitudinal online study in which measures of body mass index (BMI), disordered eating, perceived stress, attachment, social rank, mood and self-criticism/reassurance were measured at 6-monthly intervals over an 18-month period. Results: Latent Growth Curve Modelling showed that BMI increased over 18 months while stress and disordered eating decreased and that these changes were predicted by high baseline levels of these constructs. Independently of this, however, increases in stress predicted a reduction in BMI which was, itself, predicted by baseline levels of self-hatred and unfavourable social comparison. Conclusions: This study adds support to the evidence that stress is important in weight change. In addition, this is the first study to show in a longitudinal design, that social rank and self-criticism (as opposed to self-reassurance) at times of difficulty predict increases in stress and, thus, suggests a role for these constructs in weight regulation.
Collapse
|
30
|
OP0284 Comparability of The Health Assessment Questionnaire between Countries: Psychometric Examination of Cross-National Measurement Equivalence. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3985] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
SAT0080 Equivalence of Different Versions of The Health Assessment Questionnaire (HAQ) across Socio-Economic Factors in The Multi-National Quest-RA Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
THU0076 Association between Body Mass Index and Quality of Life at One and Three Years Post Diagnosis of Rheumatoid Arthritis: Results from An Inception Cohort. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
33
|
|
34
|
SP0189 Why Choose Random Effects Models for Longitudinal Datasets? Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.6364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
OP0300 Do Depressive Symptoms at Disease Onset Associate with Future Disease Activity for Adolescent Patients with Jia? Results from The Childhood Arthritis Prospective Study (CAPS). Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
36
|
THU0079 Polypharmacy, Although not Combination Dmard Therapy, in Rheumatoid Arthritis is Associated with Increased Hospitalisation Risk. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
SAT0111 The Impact of Comorbidities and Extra-Articular Manifestations on 10-Year Mortality Risk in Rheumatoid Arthritis. Results from Two Multi-Centre UK Inception Cohorts. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
FRI0075 The Impact of Comorbidity on Functional Status in RA, 10 Years from Disease-Onset. Results from Two Large Uk Inception Cohorts. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
OP0179 Different Levels of Moderate Disease in Rheumatoid Arthritis (RA) are Associated with Varying Risk for Joint Destruction and Failure. Time to Update Das Cut-Offs for Biologic Dmard Use?: Table 1. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
40
|
SAT0096 The Obesity Paradox in Rheumatoid Arthritis: Results from Uk Based Multi-Centre Observational Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Distress improves after mindfulness training for progressive MS: A pilot randomised trial. Mult Scler 2015; 21:1184-94. [PMID: 25767124 DOI: 10.1177/1352458515576261] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Accepted: 01/30/2015] [Indexed: 01/10/2023]
Abstract
BACKGROUND Mindfulness-based interventions have been shown to effectively reduce anxiety, depression and pain in patients with chronic physical illnesses. OBJECTIVES We assessed the potential effectiveness and cost-effectiveness of a specially adapted Skype distant-delivered mindfulness intervention, designed to reduce distress for people affected by primary and secondary progressive MS. METHODS Forty participants were randomly assigned to the eight-week intervention (n = 19) or a waiting-list control group (n = 21). Participants completed standardised questionnaires to measure mood, impact of MS and symptom severity, quality of life and service costs at baseline, post-intervention and three-month follow-up. RESULTS Distress scores were lower in the intervention group compared with the control group at post-intervention and follow-up (p < 0.05), effect size -0.67 post-intervention and -0.97 at follow-up. Mean scores for pain, fatigue, anxiety, depression and impact of MS were reduced for the mindfulness group compared with control group at post-therapy and follow-up; effect sizes ranged from -0.27 to -0.99 post-intervention and -0.29 to -1.12 at follow-up. There were no differences in quality-adjusted life years, but an 87.4% probability that the intervention saves on service costs and improves outcome. CONCLUSIONS A mindfulness intervention delivered through Skype video conferences appears accessible, feasible and potentially effective and cost-effective for people with progressive MS.
Collapse
|
42
|
Further development in the assessment of psychological flexibility: a shortened Committed Action Questionnaire (CAQ-8). Eur J Pain 2014; 19:677-85. [PMID: 25181605 DOI: 10.1002/ejp.589] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/16/2014] [Indexed: 11/12/2022]
Abstract
BACKGROUND Committed action is a relatively understudied facet of the psychological flexibility model but a potentially important process of overt behaviour in relation to chronic pain. In this study, we take a previously developed measure of committed action, the Committed Action Questionnaire (CAQ), and validate a shorter version. METHODS A total of 664 adults seeking treatment for chronic pain participated in this study. They provided responses to the CAQ and also completed measures of acceptance and health-related daily functioning. Exploratory and confirmatory factor analyses as well as Mokken scaling analysis were used to explore the structure of the CAQ and produce an 8-item version (CAQ-8). RESULTS A two-factor scale emerged from the analyses that both meets criteria for reliability and validity and performs comparably to the longer original version. In validity correlation analyses, committed action as measured by the CAQ-8 was significantly associated with pain-related and general acceptance and with depression, physical and social functioning, mental health, vitality and general health. CONCLUSIONS The CAQ-8 appears equally adequate as the CAQ as a measure of committed action. Its development ought to facilitate further study of this process of engagement in activity and of the wider psychological flexibility model in relation to chronic pain.
Collapse
|
43
|
THU0248 Three-Year Sustained Remission in Early RA: Predictors and Structural Outcomes. Analysis of Longitudinal Observational Data in Two Multicentre UK Inception Cohorts over 25 Years. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
OP0127 Impact of Disease Activity and Treatment on Progression of Functional Limitation in RA. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
FRI0014 Examining Baseline and 1 Year Predictors of Radiographic Progression over 5 Years Using Mixed Effects Negative Binomial Models: Results from the Early Rheumatoid Arthritis Study (ERAS) Cohort. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
OP0167 Evidence That Both the Disease Course & Structural Outcomes in RA Have Become Less Severe over Time. A 25-Year Longitudinal Data Analysis Based on Two Consecutive UK Inception Cohorts. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
THU0591-HPR The Longitudinal Impact of Persistent Depression on Physical Health Outcomes in Rheumatoid Arthritis: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
SAT0113 Common trajectories of HAQ disability progression over 15-years in the early rheumatoid arthritis study and the norfolk arthritis register. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.3060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Oral Abstracts 3: Adolescent and Young Adult * O13. Hypermobility is a Risk Factor for Musculoskeletal Pain in Adolescence: Findings From a Prospective Cohort Study. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
The use of a frailty scoring system for burns in the elderly. Burns 2013; 39:30-6. [DOI: 10.1016/j.burns.2012.03.002] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Revised: 03/02/2012] [Accepted: 03/07/2012] [Indexed: 11/24/2022]
|